These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 30975201

  • 21. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
    Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M.
    Clin Cancer Res; 2019 Nov 15; 25(22):6709-6720. PubMed ID: 31573956
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
    Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey K, Young L, Morrow M, Hammond SA, Mallinder P, Herath A, Leow CC, Wilkinson RW, Stewart R.
    Clin Cancer Res; 2017 Jul 01; 23(13):3416-3427. PubMed ID: 28069723
    [Abstract] [Full Text] [Related]

  • 24. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.
    J Immunother; 2010 Apr 01; 33(3):225-35. PubMed ID: 20445343
    [Abstract] [Full Text] [Related]

  • 25. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S.
    Proc Natl Acad Sci U S A; 2021 Jul 27; 118(30):. PubMed ID: 34301886
    [Abstract] [Full Text] [Related]

  • 26. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
    Klyushnenkova EN, Riabov VB, Kouiavskaia DV, Wietsma A, Zhan M, Alexander RB.
    Prostate; 2014 Oct 27; 74(14):1423-32. PubMed ID: 25111463
    [Abstract] [Full Text] [Related]

  • 27. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J, Lopez PA, Bialojan A, Denny M, Langguth P, Probst HC, Schild H, Radsak MP.
    J Dermatol Sci; 2017 Sep 27; 87(3):300-306. PubMed ID: 28666747
    [Abstract] [Full Text] [Related]

  • 28. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.
    Proc Natl Acad Sci U S A; 2012 Apr 17; 109(16):6187-92. PubMed ID: 22474386
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P, Bhattacharya P, Prabhakar BS.
    J Autoimmun; 2018 Dec 17; 95():77-99. PubMed ID: 30174217
    [Abstract] [Full Text] [Related]

  • 35. Clinical deployment of antibodies for treatment of melanoma.
    Curti BD, Urba WJ.
    Mol Immunol; 2015 Oct 17; 67(2 Pt A):18-27. PubMed ID: 25746916
    [Abstract] [Full Text] [Related]

  • 36. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment.
    Muthana MM, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y.
    Elife; 2023 Dec 21; 12():. PubMed ID: 38127423
    [Abstract] [Full Text] [Related]

  • 37. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
    Chen W, Pandey M, Sun H, Rolong A, Cao M, Liu D, Wang J, Zeng L, Hunter A, Lin S.
    MAbs; 2021 Dec 21; 13(1):1914359. PubMed ID: 33870864
    [Abstract] [Full Text] [Related]

  • 38. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.
    Cancer Res; 2013 Jun 15; 73(12):3591-603. PubMed ID: 23633484
    [Abstract] [Full Text] [Related]

  • 39. Regulatory T cells: a potential target in cancer immunotherapy.
    Shitara K, Nishikawa H.
    Ann N Y Acad Sci; 2018 Apr 15; 1417(1):104-115. PubMed ID: 29566262
    [Abstract] [Full Text] [Related]

  • 40. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.
    J Immunother; 2012 May 15; 35(4):344-53. PubMed ID: 22495392
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.